{
    "id": 6948,
    "fullName": "FLT3 Y842C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 Y842C lies within the protein kinase domain of the Flt3 protein (UniProt.org). Y842C results in constitutive phosphorylation of Flt3, activation of Stat5 signaling, is transforming in cell culture (PMID: 15345593), and has been demonstrated to promote secondary drug resistance in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 22504184, PMID: 29187377).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11566,
                    "pubMedId": 22504184,
                    "title": "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22504184"
                },
                {
                    "id": 2895,
                    "pubMedId": 15345593,
                    "title": "Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15345593"
                },
                {
                    "id": 11567,
                    "pubMedId": 29187377,
                    "title": "A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29187377"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "Y842C",
    "createDate": "06/02/2015",
    "updateDate": "10/04/2018",
    "referenceTranscriptCoordinates": {
        "id": 144629,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28018483T>C",
        "cDna": "c.2525A>G",
        "protein": "p.Y842C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593).",
            "molecularProfile": {
                "id": 6801,
                "profileName": "FLT3 Y842C"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2895,
                    "pubMedId": 15345593,
                    "title": "Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15345593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2323,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593).",
            "molecularProfile": {
                "id": 6801,
                "profileName": "FLT3 Y842C"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2895,
                    "pubMedId": 15345593,
                    "title": "Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15345593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Nexavar (sorafenib) in culture (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6463,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5604,
                    "pubMedId": 26822154,
                    "title": "The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26822154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2403,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Rydapt (midostaurin) in culture (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Sutent (sunitinib) in culture (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9437,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 5016,
                "therapyName": "MRX-2843",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7187,
                    "pubMedId": 27158668,
                    "title": "The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27158668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Lestaurtinib (CEP-701) in culture (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to AGL2043 in culture (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 2571,
                "therapyName": "AGL2043",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FF-10101, as compared to Quizartinib, inhibited Flt3 autophosphorylation and cell proliferation of transformed 32Dcl3 murine myeloid cells expressing a human FLT3-ITD/Y842C compound mutation (PMID: 29187377).",
            "molecularProfile": {
                "id": 19136,
                "profileName": "FLT3 exon 14 ins FLT3 Y842C"
            },
            "therapy": {
                "id": 7085,
                "therapyName": "FF-10101",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11567,
                    "pubMedId": 29187377,
                    "title": "A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29187377"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4838,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19286,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842C"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6464,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 N676D and Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",
            "molecularProfile": {
                "id": 23516,
                "profileName": "FLT3 exon 14 ins FLT3 N676D FLT3 Y842C"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5604,
                    "pubMedId": 26822154,
                    "title": "The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26822154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6801,
            "profileName": "FLT3 Y842C",
            "profileTreatmentApproaches": [
                {
                    "id": 5026,
                    "name": "FLT3 Inhibitor",
                    "profileName": "FLT3 Y842C"
                }
            ]
        },
        {
            "id": 19136,
            "profileName": "FLT3 exon 14 ins FLT3 Y842C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19286,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23516,
            "profileName": "FLT3 exon 14 ins FLT3 N676D FLT3 Y842C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144629,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28018483T>C",
            "cDna": "c.2525A>G",
            "protein": "p.Y842C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}